As shown in Supplementary Fig. 3, in COVID-19 patients with mild/moderate disease, the level of S-, RBD-, and N-specific IgM reached a high level in the second week after symptom onset, while it took 3 weeks for the severe/critical COVID-19 patients to reach comparable antibody levels. This evidence concerns the gene CD40LG and COVID-19.